Small Cap Breaking News: Don’t Miss Today’s Top Headlines 6/24/2025
AGORACOM Small Cap CEO Interviews · 2026-06-24 · 4 min
Substance score
22 / 100
Five dimensions, 20 points each
This daily small cap breaking news episode covers five major headline releases across biotech and mining sectors, including Quantum Biopharma's IND filing for an MS treatment that repairs myelin rather than suppressing immunity, New Age Metals' partnership for critical minerals processing with 98% reagent recycling, and three major mining resource updates from Oh My Gold Mines, Next Metals Mining, and Andina Copper with significantly increased resource estimates and improved strip ratios.
Key takeaways
- Quantum Biopharma's direct myelin repair mechanism for MS targets a $38.62 billion market by 2030, representing a fundamental shift from traditional immune-suppressing approaches.
- Liberate Minerals' closed-loop chemical refining process recycling 98% of reagents combined with 51.9% antimony grades materially improves project economics by reducing operating expenses.
- Oh My Gold Mines achieved a 49.8% increase in indicated resources to 1.45 million ounces through drilling results of 7.26 grams per tonne over 34.8 meters, significantly de-risking the asset.
- Next Metals Mining's 1.1 billion pound copper equivalent resource increase is most valuable because of their 1.02:1 strip ratio, shortening the path to profitability by minimizing waste rock movement.
- Andina Copper's shallow mineralization at 0.50% copper from just 38 meters depth extending 350 meters northwest indicates system scale and proximity to surface reduces development risk.
What our scoring noted
Our reviewer’s read on each dimension, with quotes from the episode.
Insight Density
The episode is a 4-minute promotional sweep across five company press releases, offering surface-level restatements of headlines with no novel analysis. Explanations are pitched at retail investors (the wire/insulation analogy) and the pace leaves no room for substantive insight beyond what is already in the company filings.
these aren't just headlines. They are actionable metrics signaling major potential inflection points
these are exactly those rare inflection points we always look for
Originality
Every claim and framing is directly derivative of company press releases; there is no contrarian argument, no first-principles reasoning, and no perspective that challenges conventional small-cap investing narratives. The episode recycles promotional language verbatim.
Will the next decade's most explosive growth come from the metals required to build our future infrastructure or the biotechnology designed to repair our own biology?
these are exactly those rare inflection points we always look for
Guest Caliber
There are no named guests and no stated credentials for either speaker; two anonymous hosts read and react to press releases in a scripted back-and-forth. No practitioner, operator, or domain expert appears.
Speaker A: Welcome to Agoracom Small Cap Breaking news, your daily go to source for the best small cap headlines for over 65 million investors since 2007
Speaker B: Yeah, these are exactly those rare inflection points we always look for
Specificity & Evidence
The episode does cite real, granular numbers pulled directly from company press releases - strip ratios, gram-per-tonne intercepts, resource ounce counts, and market-size projections - which lifts it above pure abstraction, but there is no independent verification, comparative benchmarking, or sourcing context for any figure.
7.26 grams per tonne of gold over 34.8 meters
70% resource increase yielding 1.1 billion pounds of copper equivalent
Conversational Craft
There is one moment of genuine (if brief) skepticism when Speaker A questions whether the 98% reagent recycling rate is real or 'just good spin,' but the pushback is immediately resolved without depth; the rest of the dialogue is scripted, mutually reinforcing, and designed to hype rather than probe.
I got to push back on that a bit. Yeah, a 98% Regent recycling rate sounds great for a PR deck, but, I mean, does that actually change the fundamental economic viability of a project, or is it just, you know, good spin?
That is exactly the mechanism, yes
Conversation analysis
Computed from the transcript - who did the talking, and the verbal tics along the way.
Share of words spoken
- Speaker A62%
- Speaker B38%
Filler words
Episode notes
Small Cap Breaking News You Can't Miss!Here's a quick rundown of the latest updates from standout small-cap companies making big moves today:Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM)Quantum BioPharma is advancing Lucid-MS, a patented, first-in-class drug candidate that directly targets and protects the myelin sheath destroyed in multiple sclerosis. The company has filed its IND with the FDA and is preparing to move into Phase 2 clinical trials, with a binding letter of intent already signed with global CRO Allucent. With the MS therapeutics market projected to surpass $38 billion by 2030, a therapy that protects myelin would address a major unmet need.New Age Metals Inc. (TSXV: NAM) (OTCQB: NMTLF) (FSE: P7J.F)New Age Metals has signed a Memorandum of Understanding with Australia's Liberate Minerals to evaluate applying Liberate's low-energy critical minerals refining technology across NAM's lithium, PGM, and gold-antimony portfolio. Liberate's proprietary process recycles 98% of its reagent and recovers multiple high-value metals from a single feedstock.
Full transcript
4 minTranscribed and scored by The B2B Podcast Index.
Speaker A: Welcome to Agoracom Small Cap Breaking news, your daily go to source for the best small cap headlines for over 65 million investors since 2007. Right now, uh, we are tracking a massive rethink in how we value these companies. We've got five breaking small cap releases hitting the wire today. And, I mean, they are packed with the kind of clinical and drilling metrics that, you know, demand your immediate, deeper research.
Speaker B: Yeah, these are exactly those rare inflection points we always look for. We're looking at hard data today that shifts the fundamental engineering or biological reality of a project.
Speaker A: Right, so let's jump straight into biotech. The headline here for quantum biopharma trading on the NASDAQ and CSE is QNTM is, uh, the quest to repair what multiple sclerosis takes away.
Speaker B: And the scientific hook here is just fascinating. With their candidate, lucid ms, they're bypassing the immune system entirely to directly protect the myelin sheath.
Speaker A: Wait, so instead of just suppressing the immune system, which is kind of like, I don't know, turning down the electricity flowing through a fraying wire, are they trying to actually, like, physically repair the rubber insulation itself?
Speaker B: That is exactly the mechanism, yes. And they just officially filed their IND application for it.
Speaker A: Oh, wow. So formal phase two FDA trials.
Speaker B: Exactly. And look, the financial and clinical stakes here are huge. They're targeting an Ms. Market that's projected to reach, uh, $38.62 billion by 2030. So proving this insulation effect in humans completely changes the baseline valuation of the science.
Speaker A: Right. It's all about finding that moment where the math fundamentally changes. Yeah, and, you know, from securing human health, we're transitioning to securing Western supply chains. Here's a massive processing headline for New Age Metals on the TSX venture under Nam.
Speaker B: Um, yeah, that's the MOU with Liberate Minerals.
Speaker A: Right, Exactly. New Age Metals enters into memorandum of understanding with Liberate Minerals to evaluate critical minerals processing opportunities.
Speaker B: And the standout detail there is Liberate's closed loop chemical refining process. It recycles 98% of its reagents.
Speaker A: Okay, I got to push back on that a bit. Yeah, a 98% Regent recycling rate sounds great for a PR deck, but, I mean, does that actually change the fundamental economic viability of a project, or is it just, you know, good spin?
Speaker B: Um, no, it really does change the math. Reagents are an enormous constant operating expense. Refining. So slashing that overhead, right, Combined with the fact that they're seeing grab samples showing up to, like, 51.9% antimony, which is a highly strategic metal. It means the project economics suddenly have a lot more breathing room.
Speaker A: Okay, that makes sense. So if processing tech changes the efficiency equation above ground, let's look at the hard numbers coming from below ground. I've got three rapid fire massive resource updates here. First. Oh, my gold mines. TSXV symbol OMG. They just highlighted drilling 7.26 grams per tonne of gold over 34.8 meters.
Speaker B: Right. And what's crucial there is the 49.8% increase in their indicated resource.
Speaker A: That's a huge jump.
Speaker B: It really is. It pushes them over 1.45 million ounces in that category, which dramatically de risks the asset.
Speaker A: Yeah. And then we have Next, Metals Mining, TSX V symbol NEXM M. Their headline establishes a 70% resource increase yielding 1.1 billion pounds of copper equivalent, which is huge.
Speaker B: But honestly, the metric to watch there is their incredibly low 1.02 to one strip ratio.
Speaker A: Right, because a one to one ratio means for every ton of waste rock, they're hitting a ton of valuable ore.
Speaker B: Right.
Speaker A: Uh, you aren't paying to move useless dirt.
Speaker B: Exactly. It shortens the path to profitability significantly.
Speaker A: Incredible. And Finally, Andina Copper. TSXV symbol A, N, D, C. Their headline reports intersecting 186 meters at 0.50% copper from just 38 meters down hole.
Speaker B: Yeah, and hitting those grades that close to the surface while extending that shallow mineralization 350 meters to the northwest proves this system has serious scale.
Speaker A: So, I mean, for everyone listening, these aren't just headlines. They are actionable metrics signaling major potential inflection points, whether it's FDA trials or one to one strip ratio.
Speaker B: Right. It always comes down to finding the hard data that rewrites the baseline assumptions.
Speaker A: Absolutely. So you look at these diverse small cap opportunities today. Ask yourself a question. Will the next decade's most explosive growth come from the metals required to build our future infrastructure or the biotechnology designed to repair our own biology?
More from AGORACOM Small Cap CEO Interviews
All episodes →- Small Cap Breaking News: Don’t Miss Today’s Top Headlines 6/25/202540 / 100
- HPQ’s Electric Propulsion LOI Opens A North American Drone Supply Chain Opportunity47 / 100
- Small Cap Breaking News: Don’t Miss Today’s Top Headlines 06/18/2026
- Small Cap Breaking News: Don’t Miss Today’s Top Headlines 06/17/2026
- Small Cap Breaking News: Don’t Miss Today’s Top Headlines 06/11/2026